Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2026, Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS, Reconstitution of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported strong financial performance for FY26 with standalone revenue of Rs 11,223.10 Lacs, a massive jump from Rs 294.28 Lacs in FY25. The company turned profitable with standalone net profit of Rs 37.50 Lacs compared to a loss of Rs 69.51 Lacs in the previous year. Key resignations include Mr. Hemant Amrish Parikh (Non-Executive Director, effective March 17, 2026) and Ms. Chaitra Arora (Company Secretary & Compliance Officer, effective April 30, 2026), both citing personal reasons. The Board reconstituted its committees (Audit, NRC, SRC) on May 7, 2026. The company operates in Pharmaceuticals, Agro, and Plastic polymer films segments.
The financial turnaround is positive, but two KMP resignations (Director and CS) in quick succession could raise governance concerns. Shareholders should monitor for replacement appointments, especially for the Company Secretary role which is critical for compliance.